St. Louis biotech startup Wugen inks licensing deal, hires new C-suite exec

St. Louis Business Journal

Feb 23, 2021

Wugen CEO John McKearn said the deal announced Monday builds on Wugen's "ongoing collaboration" with Washington University to create treatments for solid and hematological cancers.